Canaccord Genuity reiterated its Hold rating on Quest Diagnostics DGX and reduced its price target from $60 to $59.
Canaccord Genuity noted, "We reiterate our HOLD following soft 3Q results. Utilization, pricing, and share shift from labs to hospitals remain significant pressures, causing a lower 2012 outlook. While we appreciate the acceleration of the cost- cutting and debt repayment, we remain on the sidelines. … Lowering our 2012E revenue growth rate to 0.4% from 1.5% and our EPS estimate to $4.55 from $4.58. For 2013, we lowered our revenue growth to 0.5% from 2.1% and our EPS estimate to $4.90 from $4.95, lowering our PT to $59 from $60."
Quest Diagnostics closed at $63.37 on Tuesday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in